Please Wait.....
Report
Biomarker Deals: Terms Value and Trends 2019-2025
Market Research Report I 2025-09-10 I 125 Pages I BCC Research
Description
Report Scope
This report, Biomarker Deals: Terms, Value and Trends 2019-2025, offers a comprehensive analysis of strategic transactions, encompassing licensing, acquisitions and collaborations, in the global biomarkers industry. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.
The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.
In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.
Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.
Report Includes
- An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including a comprehensive analysis of deal structures and their potential values
- Coverage of significant companies in this study, trends and obstacles and other information affecting the development of the biomarker market
- Review of business terms and conditions of deals in the market, with focus on major trends in deal-making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
- Information essential to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
- Information about the main elements in licensing, acquisitions and partnership deals in the biomarker industry
- Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis, et al.
- Details on various types of biomarkers deals and milestone payments and their value in different deals
- Analysis of the patent landscape featuring biomarkers
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.
Executive Summary
Summary:
This report provides an analysis of strategic transactions encompassing licensing, acquisitions and collaborations in the global biomarker market. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.
The biomarker deals are gaining considerable momentum amid the rapid shift toward precision medicine, increased investment in targeted drug development and greater collaboration among biotech companies, diagnostic developers and pharmaceutical firms. Biomarkers are measurable indicators that reflect normal or abnormal biological processes, disease progression or response to therapeutic interventions. They are critical to improving clinical outcomes, accelerating drug approvals and reducing development costs. Biomarker deals include licensing deals, acquisitions, and collaborative agreements in high-impact areas like oncology, neurology, immunology and infectious disease. The deals reflect the
rising demand for companion diagnostics, predictive biomarkers and methods of detection that leverage emerging technologies in therapeutics and diagnostics.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Classification of Biomarkers
Examples of Biomarkers
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Incidence of Diseases
Advances in Omics and Imaging Technologies
Market Restraints
Development Costs
Need for Skilled Labor
Market Opportunities
Emerging Markets
Personalized Medicine
Market Challenges
Technical Challenges
Regulatory and Validation Complexity
Chapter 4 Emerging Technologies and Developments
Overview
Key Takeaways
Emerging Technologies
Genomics
Proteomics
Metabolomics
Imaging
Bioinformatics
Chapter 5 Acquisitions, Collaborations, and Licensing Deals
Licensing Deals in the Biomarker Market, 2019 to 2025
Definition and General Structure of Licensing Deals
Valuation and Payment Structure
Analysis of Licensing Deals in the Biomarker Market, 2019 to 2025
Acquisitions in the Biomarker Market, 2019 to 2025
Definition and General Structure of Acquisitions
Analysis of Acquisitions in the Biomarker Market, 2019 to 2025
Partnerships/Collaborations in Biomarker Market, 2019 to 2025
Definition and General Structure of Collaborations
Analysis of Partnerships/Collaborations in the Biomarkers Market, 2019 to 2025
Further Analysis of Deals in the Biomarker Market
Analysis of Structure of Licensing Deals, 2019 to 2025
Structure of Acquisitions in the Biomarker Industry, 2019 to 2025
Structure of Collaborations in the Biomarker Market, 2019 to 2025
Chapter 6 Biomarker Patent Landscape
Patent Landscape Takeaways
Patent Review
Chapter 7 Appendix
Methodology
Information Sources
Abbreviations
Company Profiles
ABBOTT
AGILENT TECHNOLOGIES INC.
BAYER AG
BD
BIOFOURMIS
BIOMERIEUX
BIO-RAD LABORATORIES INC.
BRUKER
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
ILLUMINA INC.
MERCK KGAA
QIAGEN
REVVITY
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : Biomarker Licensing Deals, Acquisitions and Partnerships, by Type, 2021-2025
Table 1 : Categories of Biomarkers
Table 2 : Examples of Biomarkers
Table 3 : Forms of Payment in Licensing Deals
Table 4 : Number of Biomarker Licensing Deals in Biotech Sectors, 2019-2025
Table 5 : Biomarker Licensing Deals, 2019-2025
Table 6 : Number of Biomarker Licensing Deals in Pathological Sectors, 2019-2025
Table 7 : Goals of Biomarker Licensing Deals, 2019-2025
Table 8 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
Table 9 : Number of Biomarker Acquisitions in Biotech Sectors, 2019-2025
Table 10 : Biomarker Acquisitions, 2019-2025
Table 11 : Number of Biomarker Acquisitions in Different Pathological Sectors, 2019-2025
Table 12 : Goals of Biomarker Acquisitions, 2019-2025
Table 13 : Number of Biomarker Collaborations in Biotech Sectors, 2019-2025
Table 14 : Partnerships/Collaborations in the Biomarker Market, 2019-2025
Table 15 : Number of Biomarker Collaborations in Pathological Sectors, 2019-2025
Table 16 : Goals of Biomarker Collaborations, 2019-2025
Table 17 : Up-Front Payments in Licensing Deals in the Biomarker Market, 2019-2025
Table 18 : Milestone and Royalty Payments in Licensing Deals, 2019-2025
Table 19 : Termination Conditions in Licensing Deals, 2019-2024
Table 20 : Value of Biomarker Licensing Deals Worldwide, 2021-2025
Table 21 : Acquisitions in the Biomarker Industry, 2020-2024
Table 22 : Global Value of Biomarker Acquisitions, 2021-2025
Table 23 : Up-Front Payments and Total Value in Collaboration Deals, 2019-2025
Table 24 : Percentage of Up-Front Payments from Total Value in Collaborations, 2019-2025
Table 25 : Milestones and Royalty Payments in Collaborations in the Biomarker Market, 2019-2025
Table 26 : Number of Patents and Patent Applications Filed for Biomarkers, by Year, 2019-2024
Table 27 : Patents and Patent Applications Filed for Biomarkers, 2019-2024
Table 28 : Number of Patents and Patent Applications for Biomarkers, by Company, 2019-2024
Table 29 : Information Sources for this Report
Table 30 : Abbreviations Used in this Report
Table 31 : Abbott: Company Snapshot
Table 32 : Abbott: Financial Performance, FY 2023 and 2024
Table 33 : Abbott: Product Portfolio
Table 34 : Abbott: News/Key Developments, 2023 and 2024
Table 35 : Agilent Technologies Inc.: Company Snapshot
Table 36 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 37 : Agilent Technologies Inc.: Product Portfolio
Table 38 : Agilent Technologies Inc.: News/Key Developments, 2023 and 2024
Table 39 : Bayer AG: Company Snapshot
Table 40 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 41 : Bayer AG: Product Portfolio
Table 42 : Bayer AG: News/Key Developments, 2024
Table 43 : BD: Company Snapshot
Table 44 : BD: Financial Performance, FY 2023 and 2024
Table 45 : BD: Product Portfolio
Table 46 : BD: News/Key Developments, 2024
Table 47 : Biofourmis: Company Snapshot
Table 48 : Biofourmis: Product Portfolio
Table 49 : Biofourmis: News/Key Developments, 2020 and 2024
Table 50 : bioMerieux: Company Snapshot
Table 51 : bioMerieux: Financial Performance, FY 2023 and 2024
Table 52 : bioMerieux: Product Portfolio
Table 53 : bioMerieux: News/Key Developments, 2024
Table 54 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 55 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 56 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 57 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024
Table 58 : Bruker: Company Snapshot
Table 59 : Bruker: Financial Performance, FY 2023 and 2024
Table 60 : Bruker: Product Portfolio
Table 61 : Bruker: News/Key Developments, 2023
Table 62 : Danaher Corp.: Company Snapshot
Table 63 : Danaher Corp.: Financial Performance, FY 2023 and 2024
Table 64 : Danaher Corp.: Product Portfolio
Table 65 : Danaher Corp.: News/Key Developments, 2022-2024
Table 66 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 67 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 68 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 69 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
Table 70 : Illumina Inc.: Company Snapshot
Table 71 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 72 : Illumina Inc.: Product Portfolio
Table 73 : Illumina Inc.: News/Key Developments, 2024
Table 74 : Merck KGaA: Company Snapshot
Table 75 : Merck KGaA: Financial Performance, FY 2023 and 2024
Table 76 : Merck KGaA: Product Portfolio
Table 77 : Merck KGaA: News/Key Developments, 2024
Table 78 : Qiagen: Company Snapshot
Table 79 : Qiagen: Financial Performance, FY 2023 and 2024
Table 80 : Qiagen: Product Portfolio
Table 81 : Qiagen: News/Key Developments, 2023 and 2024
Table 82 : Revvity: Company Snapshot
Table 83 : Revvity: Financial Performance, FY 2023 and 2024
Table 84 : Revvity: Product Portfolio
Table 85 : Revvity: News/Key Developments, 2022 and 2023
Table 86 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 87 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 88 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 89 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
List of Figures
Figure 1 : Market Dynamics Snapshot
Figure 2 : Share of Biomarker Licensing Deals, by Therapeutic Area, 2019-2025
Figure 3 : Share of Biomarker Licensing Deals, by Goal, 2019-2025
Figure 4 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
Figure 5 : Share of Biomarker Acquisitions in Pathological Sectors, 2019-2025
Figure 6 : Share of Biomarker Acquisitions, by Goal, 2019-2025
Figure 7 : Share of Biomarker Collaborations in Biotech Sectors, by Year, 2019-2025
Figure 8 : Share of Biomarker Collaborations in Pathological Sectors, 2019-2025
Figure 9 : Share of Biomarker Collaborations, by Goal, 2019-2025
Figure 10 : Share of Collaborations Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
Figure 13 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
Figure 14 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
Figure 15 : Bayer AG: Revenue Share, by Business Unit, FY 2024
Figure 16 : Bayer AG: Revenue Share, by Country/Region, FY 2024
Figure 17 : BD: Revenue Share, by Business Unit, FY 2024
Figure 18 : BD: Revenue Share, by Country/Region, FY 2024
Figure 19 : bioMerieux: Revenue Share, by Business Unit, FY 2024
Figure 20 : bioMerieux: Revenue Share, by Country/Region, FY 2024
Figure 21 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 23 : Bruker: Revenue Share, by Business Unit, FY 2024
Figure 24 : Bruker: Revenue Share, by Business Unit, FY 2024
Figure 25 : Danaher Corp.: Revenue Share, by Business Unit, FY 2024
Figure 26 : Danaher Corp.: Revenue Share, by Country/Region, FY 2024
Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 28 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 29 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 30 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 31 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 32 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
Figure 33 : Qiagen: Revenue Share, by Business Unit, FY 2024
Figure 34 : Qiagen: Revenue Share, by Country/Region, FY 2024
Figure 35 : Revvity: Revenue Share, by Business Unit, FY 2024
Figure 36 : Revvity: Revenue Share, by Country/Region, FY 2024
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security